Experiments in a variety of tumor types have shown that sensitivity to TRAIL is controlled by numerous factors including the levels of expression of DR4, DR5, and C8, receptor glycosylation and resistance genes for decoy receptors and cFLIP (reviewed by Dimberg et al (2013)). Here, CFLAR is linked to neoplasm.